NICE wants more data on Simponi for rheumatoid arthritis
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, wants more information on the clinical- and cost-effectiveness of Merck & Co/J&J's rheumatoid arthritis (RA) drug Simponi (golimumab) before it can decide whether to recommend its use in the NHS.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.